Technical Analysis for CRNX - Crinetics Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
B 53.58 1.75% 0.92
CRNX closed up 1.75 percent on Monday, July 22, 2024, on 78 percent of normal volume.
Earnings due: Aug 8
*** please verify all earnings dates ***
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.75%
NR7 Range Contraction 1.75%
Inside Day Range Contraction 1.75%
Wide Bands Range Expansion 1.75%
Gapped Up Strength 1.75%
Overbought Stochastic Strength 1.75%
Wide Bands Range Expansion 2.23%
Overbought Stochastic Strength 2.23%
Slingshot Bullish Bullish Swing Setup -0.50%

   Recent Intraday Alerts

Alert Time
10 DMA Support about 13 hours ago
60 Minute Opening Range Breakdown about 13 hours ago
Fell Below 10 DMA about 13 hours ago
Non-ADX 1,2,3,4 Pullback Entry about 15 hours ago
Rose Above Previous Day's High about 15 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Crinetics Pharmaceuticals, Inc. Description

Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. The Company is focused on the discovery and development of drugs to treat specialty endocrine diseases and endocrine-related tumors. It develops a pipeline of oral nonpeptide chemical entities that target peptide G protein coupled receptors (GPCRs) for the treatment of endocrine diseases. The Company’s lead product candidate is CRN00808 developed for the treatment of acromegaly. It also develops two other product candidates CRN02481 for hyperinsulinemia, and CRN01941 for the treatment of neuroendocrine tumors. CRN02481 and CRN01941 are both oral nonpeptide somastatin receptors that are in the pre-clinical stages of development. The company also conducts research programs on developing nonpeptide products for the treatment of Cushing’s disease.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Disease Organ Systems Pancreatic Cancer Endocrine System Insulin Stage Pharmaceutical Chemical Entities Neuroendocrine Tumors Acromegaly Neuroendocrine Tumor Endocrine Disease Endocrine Diseases Neuroendocrinology

Is CRNX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 55.77
52 Week Low 15.76
Average Volume 996,367
200-Day Moving Average 39.63
50-Day Moving Average 47.82
20-Day Moving Average 48.66
10-Day Moving Average 52.71
Average True Range 2.04
RSI (14) 64.41
ADX 23.66
+DI 35.17
-DI 18.06
Chandelier Exit (Long, 3 ATRs) 49.64
Chandelier Exit (Short, 3 ATRs) 47.14
Upper Bollinger Bands 57.33
Lower Bollinger Band 39.99
Percent B (%b) 0.78
BandWidth 35.64
MACD Line 2.13
MACD Signal Line 1.56
MACD Histogram 0.5745
Fundamentals Value
Market Cap 3.58 Billion
Num Shares 66.8 Million
EPS -3.64
Price-to-Earnings (P/E) Ratio -14.72
Price-to-Sales 558.22
Price-to-Book 4.82
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 56.03
Resistance 3 (R3) 55.90 54.94 55.62
Resistance 2 (R2) 54.94 54.32 55.01 55.49
Resistance 1 (R1) 54.26 53.93 54.60 54.40 55.35
Pivot Point 53.31 53.31 53.48 53.37 53.31
Support 1 (S1) 52.63 52.68 52.97 52.76 51.81
Support 2 (S2) 51.67 52.29 51.74 51.67
Support 3 (S3) 50.99 51.67 51.54
Support 4 (S4) 51.13